ELAA Technology has developed a patent pending Pure Digital Medical Navigation Platform for cancer early diagnosis of certain types of cancer. The first product utilizing this platform technology is PRECIMON™ for lung cancer.
Lung cancer is by far the leading cause of cancer death among both men and women, making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.
PRECIMON™ Pure Digital Lung Navigation System is a Class-II software as a medical device to be used in conjunction with any bronchoscopy unit in the market. By providing patient's Computerized Tomography (CT) images and bronchoscopy camera feed, PRECIMON™ is able to localize target lesion and support early diagnosis of suspicious lesions with almost 100% accuracy.
In order to detect and take samples from a target lesion our software transforms CT images into virtual 3D airway and blood vessel volumes and our system asks operator to mark the lesion on user interface. Then the system calculates the safest route to lesion to eliminate risks of bleeding inside lungs. Calculated route will be shown on both virtual and real bronchoscopy video frames to lead operator into the lesion. At the end operator will be able to see where the lesion is and which angle bronchoscopy needle should take sample from it. Herebelow is a screenshot of the main screen of the device.



⦁ Visual bronchoscopy image created by the PRECIMON™ server
⦁ Real-time image from the bronchoscopy device
⦁ Representative map showing the target site, route and the position of the camera
⦁ Vein structure and bronchial maps created by the PRECIMON™ server

PRECIMON is registered as a Class-II Medical Device and has a CE Certificate
(# 2195-MED-2008701) valid until May 2024.